
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Jun 23
Feb 23
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read MoreIn 2019, Innoplexus worked with Novartis on a pilot program that used Innoplexus’s proprietary artificial intelligence solutions and publicly available data to seek to identify baseline biomarkers of response.
Innoplexus was talking to Eric Hughes – global development unit head for immunology, hepatology, and dermatology at Novartis:
Eric Hughes: I am the Development Unit Head of Immunology, Hepatology, Dermatology and the China Head of Global Drug Development. I lead the discussions with Innoplexus in terms of defining the high-level strategy for the biomarker identification project.
Eric Hughes: At Novartis, leveraging data and digital is critical to our strategy. As an example, leveraging advances in machine learning and our internal clinical and omics data provides the potential of identifying subgroups of patients most likely to respond to a particular treatment. When we look for a technology provider, we are looking for a partner that is driving the advances in the field that will help us deliver transformational treatments for patients.
Eric Hughes: What impressed me about Innoplexus is their technology, how they listened to what we wanted to achieve, and how quickly they executed the project.
Eric Hughes: We had a positive experience with the Innoplexus team during this pilot program. The Innoplexus team was very fast to develop their strategy to address our request. During the execution of the project, the Innoplexus team scheduled regular check-ins with our team to share progress and ask clarifying questions in case any changes in strategy were needed to complete the project to our expectations.
Eric Hughes: Having sufficient data and the analytical capability is critical to being able to identify potential baseline biomarkers of response for the autoimmune diseases we are focused on at Novartis. In working with Innoplexus our expectation was to leverage their technology to pool all of the publicly available patient-level data that might help us in delivering on this objective.
About Eric Hughes:
Eric Hughes joined Novartis in 2015 as the global development unit head for immunology, hepatology, and dermatology. Later, he was also appointed as the China Head of Global Drug Development. Hughes is a licensed physician with specialty training in infectious diseases. He has a doctoral degree in immunology from Yale. He oversees clinical development for therapies and looks forward to helping Novartis deliver transformational treatments for patients.
About Innoplexus:
Innoplexus provides advanced artificial intelligence and blockchain solutions that support all stages of drug development from pipeline to market. Innoplexus identifies and extracts structured and unstructured life science data by scanning up to 95% of the world-wide-web and merges it with enterprise and third-party data in an ongoing, real-time process. This continually updated data repository is the foundation of our custom and off-the-shelf solutions.
The cost of developing a new drug roughly doubles every nine years (inflation-adjusted) aka Eroom’s law.As the volume of data…
There was a time when science depended on manual efforts by scientists and researchers. Then, came an avalanche of data…
Collaboration with key opinion leaders and influencers becomes crucial at various stages of the drug development chain. When a pharmaceutical…
Data are not the new gold – but the ability to put them together in a relevant and analyzable way…
Artificial intelligence, or AI, is gaining more attention in the pharma space these days. At one time evoking images from…
Artificial intelligence (AI) is transforming the pharmaceutical industry with extraordinary innovations that are automating processes at every stage of drug…
There is a lot of buzz these days about how artificial intelligence (AI) is going to disrupt the pharmaceutical industry….
Drug discovery plays a key role in the pharma and biotech industries. Discovering unmet needs, pinpointing the target, identifying the…
The pharmaceutical industry spends billions on R&D each year. Clinical trials require tremendous amounts of effort, from identifying sites and…
Training algorithms to identify and extract Life Sciences-specific data The English dictionary is full of words and definitions that can be…
The early 1970s introduced the world to the idea of computer vision, a promising technology automating tasks that would otherwise…
Summary:AI could potentially speed drug discovery and save time in rejecting treatments that are unlikely to yield worthwhile resultsAI has…